Can-Fite BioPharma (CANF)
XASE:CANF
Top Page
Can-Fite BioPharma
(NYSE MKT:CANF)
Select Model
Select Model
Rating:41Neutral
Price Target:
$3.00
▼(-25.74% Downside)
Action:ReiteratedDate:03/28/26
The score is held down primarily by weak financial performance (declining revenue, ongoing losses, and persistent cash burn) and bearish technical signals (price below key moving averages with negative MACD). Low leverage provides some risk mitigation, but valuation is not supportive given losses and no dividend data.
Positive Factors
Strengthened global IP for Namodenoson (anti‑obesity)
A multi‑jurisdiction patent estate around Namodenoson’s anti‑obesity use creates a durable barrier to direct copycat entrants, improves bargaining leverage for licensing or partnerships, and underpins longer‑term commercialization options across major markets if clinical efficacy is proven.
Negative Factors
Consistent negative operating and free cash flow
Ongoing negative cash flow is a structural constraint: it necessitates recurring external financing, can force program prioritization or delays, and raises dilution risk. Persistent burn limits the firm’s ability to scale development activities without predictable, long‑term funding sources.
Read all positive and negative factors
Positive Factors
Negative Factors
Strengthened global IP for Namodenoson (anti‑obesity)
A multi‑jurisdiction patent estate around Namodenoson’s anti‑obesity use creates a durable barrier to direct copycat entrants, improves bargaining leverage for licensing or partnerships, and underpins longer‑term commercialization options across major markets if clinical efficacy is proven.
Read all positive factors
Can-Fite BioPharma (CANF) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.25M
Dividend YieldN/A
Average Volume (3M)258.05K
Price to Earnings (P/E)―
Beta (1Y)1.08
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.13
Shares Outstanding2,142,546
10 Day Avg. Volume432,468
30 Day Avg. Volume258,053
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.59
Price to Sales (P/S)8.07
P/FCF Ratio-0.37
Enterprise Value/Market Cap1.12K
Enterprise Value/Revenue14.54K
Enterprise Value/Gross Profit14.54K
Enterprise Value/Ebitda-914.26
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.72
Revenue Forecast (FY)N/A
Can-Fite BioPharma Business Overview & Revenue Model
Company Description
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, w...
How the Company Makes Money
null...
Can-Fite BioPharma Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 560.00K | 408.21K | 674.00K | 743.00K | 810.00K | 853.00K |
| Gross Profit | 560.00K | 384.02K | 674.00K | 743.00K | 810.00K | 853.00K |
| EBITDA | -8.90M | -10.00M | -8.12M | -8.18M | -10.08M | -12.83M |
| Net Income | -8.80M | -9.91M | -7.88M | -7.63M | -10.17M | -12.60M |
Balance Sheet | ||||||
| Total Assets | 7.72M | 9.51M | 9.12M | 9.99M | 9.28M | 20.25M |
| Cash, Cash Equivalents and Short-Term Investments | 6.46M | 8.54M | 7.89M | 8.92M | 7.98M | 19.14M |
| Total Debt | 90.00K | 71.00K | 104.00K | 40.00K | 62.00K | 124.00K |
| Total Liabilities | 3.54M | 3.92M | 3.68M | 3.75M | 4.81M | 5.87M |
| Stockholders Equity | 4.18M | 5.59M | 5.44M | 6.24M | 4.47M | 14.38M |
Cash Flow | ||||||
| Free Cash Flow | -8.36M | -9.02M | -7.64M | -8.44M | -10.81M | -9.87M |
| Operating Cash Flow | -8.35M | -9.02M | -7.64M | -8.44M | -10.80M | -9.86M |
| Investing Cash Flow | -2.00K | -2.02K | 1.50M | 498.00K | 9.50M | -14.51M |
| Financing Cash Flow | 10.08M | 9.72M | 6.71M | 9.14M | 0.00 | 20.46M |
Can-Fite BioPharma Technical Analysis
Negative
4.04
Price Trends
3.99
Negative
4.71
Negative
9.35
Negative
Market Momentum
-0.31
Negative
36.79
Neutral
24.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CANF, the sentiment is Negative. The current price of 4.04 is above the 20-day moving average (MA) of 3.29, above the 50-day MA of 3.99, and below the 200-day MA of 9.35, indicating a bearish trend. The MACD of -0.31 indicates Negative momentum. The RSI at 36.79 is Neutral, neither overbought nor oversold. The STOCH value of 24.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CANF.
Can-Fite BioPharma Risk Analysis
Can-Fite BioPharma disclosed 68 risk factors in its most recent earnings report. Can-Fite BioPharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
If a United States person is treated as owning at least 10% of our shares, such holder may be subject to adverse U.S. federal income tax consequences. Q4, 2023
Can-Fite BioPharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $13.24M | -1.01 | -317.47% | ― | -100.00% | 58.50% | |
45 Neutral | $8.03M | -0.55 | -257.81% | ― | ― | 72.88% | |
41 Neutral | $7.25M | -0.33 | ― | ― | ― | ― | |
41 Neutral | $4.62M | -3.61 | -154.50% | ― | ― | 54.25% |
* Healthcare Sector Average
CANF
Can-Fite BioPharma
3.08
-24.88
-88.98%
GNPX
Genprex
1.31
-11.94
-90.11%
BCDA
BioCardia
1.21
-0.72
-37.31%
PCSA
Processa Pharmaceuticals
3.02
-3.48
-53.54%
PHGE
BiomX
2.90
-7.15
-71.14%
Can-Fite BioPharma Corporate Events
Can-Fite BioPharma Posts 2025 Loss but Highlights Long-Term Cancer Survival and Clinical Progress
Mar 26, 2026
On March 26, 2026, Can-Fite BioPharma reported its 2025 results and recent clinical milestones, highlighting that a Phase 2a trial in heavily pretreated pancreatic cancer patients met its primary safety endpoint, with over 30% of patients alive at...
Can-Fite Secures Israeli Patent to Bolster Namodenoson Anti-Obesity Franchise
Mar 17, 2026
On March 17, 2026, Can-Fite BioPharma announced that the Israeli Patent Office allowed its patent application covering the use of A3 adenosine receptor agonists, including lead candidate Namodenoson, for fat loss and treatment of obesity and relat...
Can-Fite BioPharma Shareholders Approve All Proposals at March 10 Special Meeting
Mar 10, 2026
On March 10, 2026, Can-Fite BioPharma held a Special General Meeting of Shareholders at which investors approved all three proposals that had been put to a vote, each receiving the required majority. The measures, originally outlined in a January ...
Can-Fite BioPharma Secures $4 Million via Repriced Warrant Exercise to Fund Clinical Pipeline
Mar 5, 2026
On March 4, 2026, Can-Fite BioPharma entered a definitive inducement agreement with a warrant holder for the immediate cash exercise of outstanding warrants to purchase 795,869 ADSs, cutting the exercise price from $9.34 to $5.00 per ADS. The tran...
Can-Fite’s Namodenoson Clears Phase 2a Safety Bar in Advanced Pancreatic Cancer
Mar 4, 2026
On March 4, 2026, Can-Fite BioPharma reported that its Phase 2a open-label study of namodenoson in patients with advanced pancreatic ductal adenocarcinoma who had failed prior systemic therapies successfully met its primary endpoint of safety. Nam...
Can-Fite BioPharma Adjourns Special Shareholders’ Meeting to March 10, 2026
Mar 4, 2026
On March 3, 2026, Can-Fite BioPharma Ltd. convened a Special General Meeting of Shareholders in Ramat Gan, Israel, but the session could not proceed due to a lack of quorum. As a result, the company adjourned the gathering for one week and schedul...
Can-Fite Showcases Namodenoson Anti-Obesity Data in Peer-Reviewed Journal
Feb 17, 2026
On February 17, 2026, Can-Fite BioPharma reported a peer-reviewed publication in the International Journal of Obesity showing that its lead drug namodenoson has a significant anti‑obesity effect in preclinical models. The study found that na...
Can-Fite BioPharma Wins Canadian Patent Allowance for Namodenoson Obesity Use
Feb 9, 2026
On February 9, 2026, Can-Fite BioPharma announced that the Canadian Patent Office issued a notice of allowance for a patent covering the use of its orally administered A3 adenosine receptor agonist Namodenoson to reduce fat mass and body weight. T...
Can-Fite Reports Successful Liver Transplant After Compassionate Use of Namodenoson
Feb 5, 2026
On February 5, 2026, Can-Fite BioPharma reported that a patient with advanced decompensated liver cirrhosis treated with its investigational drug Namodenoson under a compassionate use program subsequently underwent a successful liver transplant. A...
Can-Fite BioPharma Calls March 3 Special Meeting to Address NYSE Audit Committee Non-Compliance
Jan 27, 2026
On January 27, 2026, Can-Fite BioPharma announced it will convene a Special General Meeting of Shareholders on March 3, 2026 in Ramat Gan, Israel, where investors will vote on electing Ilan Tamir as an external director for a three‑year term...
Can-Fite Completes Enrollment in Phase 2a Pancreatic Cancer Trial of Namodenoson
Jan 20, 2026
On January 20, 2026, Can-Fite BioPharma announced it had completed patient enrollment in its multicenter, open-label Phase 2a pancreatic cancer trial of Namodenoson, which is testing safety, clinical activity and pharmacokinetics in patients with ...
Can-Fite BioPharma Discloses Resignation of Director Yaacov Goldman
Jan 16, 2026
On January 14, 2026, Can-Fite BioPharma Ltd. announced that board member Yaacov Goldman resigned from the company’s Board of Directors and all board committees, effective immediately, citing personal reasons and affirming that his departure ...
Can-Fite BioPharma Secures Brazilian Patent for A3AR-Based Sexual Dysfunction Therapy
Dec 29, 2025
On December 26, 2025, Can-Fite BioPharma announced that Brazil’s patent office granted a patent protecting the use of its A3 adenosine receptor agonist technology for the treatment of sexual dysfunction, extending its intellectual property c...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.